Focused On-demand Library for Plexin-A1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UIW2

UPID:

PLXA1_HUMAN

Alternative names:

Semaphorin receptor NOV

Alternative UPACC:

Q9UIW2

Background:

Plexin-A1, also known as Semaphorin receptor NOV, is a pivotal protein in the nervous system. It serves as a coreceptor for SEMA3A, SEMA3C, SEMA3F, and SEMA6D, playing a crucial role in axon guidance, cell migration, and cytoskeleton remodeling. This protein's interaction with class 3 semaphorins and the subsequent activation of downstream signaling pathways underscore its importance in neural development and function.

Therapeutic significance:

Plexin-A1's involvement in Dworschak-Punetha neurodevelopmental syndrome, characterized by developmental delays, autism spectrum disorder, and other neurological abnormalities, highlights its potential as a therapeutic target. Understanding the role of Plexin-A1 could open doors to potential therapeutic strategies for treating or managing this syndrome and possibly other neurodevelopmental disorders.